Published in Drug Week, November 9th, 2001
The study showed that chronic administration of the formulation appears to cause no changes in the epithelial cells of the mouth, nor was there any evidence of toxic injury. Safety and efficacy trials studying Oralin in humans are ongoing.
The dog study was conducted by Dr. Dana Allen, DVM, MSc, Diplomate ACVIM (Internal Medicine), professor at the University of Guelph, Ontario Veterinary College in Guelph, Ontario, Canada. Allen is the author of more than 100...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.